Latest Filings

Issuer Activity

Insider Overview :: Microbix Biosystems Inc. (T:MBX) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for MBX within the last 6 months [?]
Amended Filing
As of 11:59pm ET March 26th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 19/15 Mar 19/15 Blecher, Peter Martin Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 19/15 Mar 19/15 Blecher, Peter Martin Direct Ownership Options 51 - Exercise of options -100,000  
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Common Shares 11 - Disposition carried out privately -100,000 $0.390
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Options 51 - Exercise of options -100,000  
Mar 17/15 Mar 16/15 Pollock, Andrew Christopher Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 17/15 Mar 16/15 Pollock, Andrew Christopher Direct Ownership Options 51 - Exercise of options -100,000  
Mar 11/15 Mar 11/15 Pollock, Andrew Christopher Direct Ownership Common Shares 10 - Disposition in the public market -100,000 $0.520
Mar 10/15 Mar 10/15 Renner, Joseph David Direct Ownership Common Shares 51 - Exercise of options 500,000 $0.360
Mar 10/15 Mar 10/15 Renner, Joseph David Direct Ownership Common Shares 54 - Exercise of warrants 185,185 $0.400
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for MBX within the last 6 months [?]
Amended Filing
As of 11:59pm ET March 26th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 19/15 Mar 19/15 Blecher, Peter Martin Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 19/15 Mar 19/15 Blecher, Peter Martin Direct Ownership Options 51 - Exercise of options -100,000  
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Common Shares 11 - Disposition carried out privately -100,000 $0.390
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 19/15 Mar 19/15 Cochran, Mark Direct Ownership Options 51 - Exercise of options -100,000  
Mar 17/15 Mar 16/15 Pollock, Andrew Christopher Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.360
Mar 17/15 Mar 16/15 Pollock, Andrew Christopher Direct Ownership Options 51 - Exercise of options -100,000  
Mar 11/15 Mar 9/15 Luscher, Mark Adrian Direct Ownership Options 50 - Grant of options 300,000 $0.560
Mar 11/15 Mar 11/15 Pollock, Andrew Christopher Direct Ownership Common Shares 10 - Disposition in the public market -100,000 $0.520
Mar 10/15 Mar 10/15 Renner, Joseph David Direct Ownership Common Shares 51 - Exercise of options 500,000 $0.360
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for MBX on March 26, 2015 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Key People
William J. Gastle
Executive Chairman of the Board
Vaughn C. Embro-Pantalony
President, Chief Executive Officer, Director
Charles S. Wallace
Chief Financial Officer
Company Contact
Address: 265 Watline Ave
MISSISSAUGA ON L4Z 1P3
Tel: N/A
Website: microbix.com
IR: See website
Business Overview
Microbix Biosystems Inc is a Canada-based Company engaged in developing biological products and technologies. The Company developed a pipeline of selected biological technologies including Virusmax (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology) and the thrombolytic drug, Kinlytic (Urokinase). The Company specializes in developing biological technologies, which leads to the development of a pipeline of products in three areas biotherapeutics, vaccines and non-therapeutic biologics. The Company's product categories include Infectious Disease Antigens, Proficiency Testing and Adenovirus Vectors. The Virology business develops, manufactures and distributes infectious disease antigens for the medical diagnostic and vaccine research industries. The Company has commercialized approximately 60 products derived from infectious pathogens cultured and processed at its facilities.
Financial Overview
For the three months ended 31 December 2014, Microbix Biosystems, Inc. revenues increased 4% to C$2M. Net income decreased 98% to C$2K. Revenues reflect Europe segment increase of 28% to C$1.7M. Net income was offset by Employee benefits in SGA increase from C$114K to C$242K (expense), Interest expense increase of 27% to C$157K (expense).
Employees: 20 as of Sep 30, 2002
Reporting Currency: Canadian Dollars
Enterprise value: $50.78M as of Dec 31, 2014
Annual revenue (TTM): $8.46M as of Dec 31, 2014
EBITDA (TTM): $1.59M as of Dec 31, 2014
Net annual income (TTM): $0.05M as of Dec 31, 2014
Free cash flow (TTM): -$5.34M as of Dec 31, 2014
Net Debt Last Fiscal Year: $5.72M as of Dec 31, 2014
Shares outstanding: 79,663,486 as of Mar 23, 2015
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
ImmunoVaccine (T:IMV)
AEterna Zentaris (T:AEZ)
Neptune Tech & Biores (T:NTB)
 
Microbix Biosystems Inc. Insider Report Only $20.00